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with Peripheral-Blood Mononuclear Cells In Vivo
Philipp Kaiser, Barbara Niedero¨st, Beda Joos, Viktor von Wyl, Milos Opravil, Rainer Weber, Huldrych F. Gu¨nthard,
and Marek Fischer
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zu¨rich, Zu¨rich, Switzerland
Background. Hepatitis C virus (HCV) replicating in peripheral-blood mononuclear cells (PBMCs) may rep-
resent an extrahepatic viral reservoir. Quantitation of HCV RNA with regard to its subcellular distribution and
longitudinal course is needed for better understanding of the largely unexplored in vivo dynamics and potential
pathogenetic significance of HCV in PBMCs.
Methods. Plasma and PBMCs from 30 patients coinfected with HCV and human immunodeficiency virus
were evaluated in cross-sectional and longitudinal analyses, for up to 40 months. Differential extraction of virion-
enclosed HCV RNA associated with cells was performed in parallel with extraction of total cellular HCV RNA.
HCV RNA of either orientation was quantified by real-time polymerase chain reaction.
Results. HCV RNA was detected only in PBMCs from patients with viremia and at relatively stable quantities
over time. Intracellular HCV RNA corresponding to ∼60% of total cellular HCV RNA was strongly correlated
with virion-enclosed HCV RNA but was only weakly associated with viral loads in plasma. In contrast, the ratio
of HCV RNA load in PBMCs versus that in plasma was patient specific and stable over time.
Conclusions. The substantial and patient-specific amounts of intracellular HCV RNA found by the present
study support a concept of low-level replication in PBMCs. There was no evidence for persistent HCV infection
in PBMCs after clearance of viremia in plasma.
Hepatitis C Virus (HCV) is a small positive-strand RNA
virus responsible for a heavy worldwide burden of
chronic hepatitis, liver cirrhosis, and hepatocellular car-
cinoma. Although primarily hepatotropic, HCV is also
assumed to replicate, to some degree, at extrahepatic
sites [1–4], with peripheral-blood mononuclear cells
(PBMCs) being the site most investigated. Evidence for
low-level replication at this site has been drawn mainly
from detection of either negative-strand replicative in-
termediates [5, 6] or cell-bound HCV antigens, in-
cluding nonstructural proteins [7, 8]. Moreover, HCV
quasi species or genotypes may be compartmentalized
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between plasma and PBMCs [9–11]. Finally, transient
low-level HCV propagation can occasionally be ob-
served in ex vivo leukocyte cultures [12, 13].
The concept of HCV lymphotropism is further sup-
ported by overrepresentation of certain lymphoprolif-
erative disorders in HCV-infected persons [14] and
may affect the pathogenesis and course of HCV infec-
tion. Reports of both recurrence of HCV viremia in
immunocompromised hosts after years of sustained vi-
ral response [15] and posttransplantation recurrence
after successful pretransplantation antiviral treatment
[16, 17] indicate that HCV may persist for years in a
reservoir of long-lived lymphoid cells [18], precisely
because they do not support vigorous replication and
therefore may offer shelter from the immune system.
Indeed, HCV RNA of either orientation could be de-
tected occasionally in PBMCs of persons who had
achieved sustained clearance of HCV viremia in plas-
ma for up to 9 years beforehand [19, 20]. In support
of the potential implications that HCV infection of
PBMCs has for horizontal as well as vertical spread of
disease, the risk of mother-to-child transmission has
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Table 1. Characteristics of and basic polymerase-chain-reaction data on patients with hepatitis C virus (HCV) viremia.
Patient (sex; age
at first visit, years)
HCV
genotypea
Sample (time
point, monthsb)
CD4 cell
count, no./mL
PBMC-associated
HCV RNA, log10
copies/5  106 cellsc
Viral load
in plasma, copies/mL Totald
Virion
encloseddHIV HCV, log10
d
Positive
strand
Negative
strand
1 (M; 46) 3A 1 (0) 483 1234e 7.9 5.3 + 5.0
2 (M; 37) 4C/D 1 (0) 381f 1208e 7.9 5.2 + 5.0
3 (M; 41) 3A 1 (0) 211 !5e 6.6 5.6 + 5.6
4 (M; 29) NA 1 (0) 189 7702e 6.1 2.4  2.6
5 (M; 32) NA 1 (0) 1024 1220e 6.3 3.3  3.5
6 (M; 44) 1A/B 1 (0) 321 !7e 5.6 4.3  3.9
7 (M; 36) 1a 1 (0) 1135f !7e 7.6 5.1 + 5.0
8 (M; 27) 1B 1 (0) 597 !50e 6.4 3.1  2.5
9 (M; 39) 4 1 (0) 392 !6e 6.5 2.9  2.4
2 (5) 427 11e 7.0 3.4  2.9
10 (M; 30) 1A 1 (0) 251 !4e 6.7 4.7  4.6
2 (6) 309 !6e 7.4 5.0  4.1
11 (M; 42) 1B 1 (0) 314 !3e 7.2 4.6  4.6
2 (4) 387f !4e 6.5 4.5  4.7
12 (M; 33) NA 1 (0) 599f 19e 6.8 4.3  4.7
2 (1) 609 !5e 7.5 4.2  4.2
13 (M; 33) 4C/D 1 (0) 302 3,900,000 8.3 3.4  3.3
2 (0.4) 519 1,950,655 7.8 3.0  2.7
3 (1.6) 735 1310e 7.0 2.4  2.3
4 (3) 737 57e   ND ND
14 (M; 35) 1A 1 (0) 308 273e 6.8 3.9  3.4
2 (6) 193 217e 7.0 4.7  4.5
3 (11) 131 117e 7.6 4.0  3.5
15 (F; 38) NA 1 (0) 598 !5e 7.6 4.6  3.8
2 (4) 671f !6e 7.9 5.1  4.9
3 (11) 877 !5e 6.7 5.4  4.9
16 (F; 32) 3A 1 (0) 872 !6e 6.6 0.9  
2 (15) 775 !7e 6.8 1.4  
3 (18) 872 !6e 7.1 1.7  1.3
4 (22) 398 !9e 1.8   
5 (24) 301 !9e   ND ND
17 (M; 45) NA 1 (0) 494 !24e 3.9 2.6  1.9
2 (4) 970f 16e 5.0 2.7  2.7
3 (7) 994 23,341 4.9 2.5  1.8
4 (10) 617f 30,000 4.4 2.6  1.9
5 (11) 509 3780 3.5 2.1  1.3
6 (14) 440 8130 5.0 2.8  2.5
7 (17) 474 4120 5.1 2.1  1.7
(continued)
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Table 1. (Continued.)
Patient (sex; age
at first visit, years)
HCV
genotypea
Sample (time
point, monthsb)
CD4 cell
count, no./mL
PBMC-associated
HCV RNA, log10
copies/5  106 cellsc
Viral load
in plasma, copies/mL Totald
Virion
encloseddHIV HCV, log10
d
Positive
strand
Negative
strand
18 (F; 40) 3A 1 (0) 1335 !7e 4.7 2.4  2.2
2 (5) 789 1233 2.8   
3 (13) 529 112 4.2 2.0  1.6
4 (18) 727 1034 5.1 2.7  2.3
5 (24) 741 191 5.5 2.8  2.5
6 (30) 496 1960 5.6 2.9  2.5
7 (35) 402 4610 5.8 2.5  1.8
8 (36) 483 19 4.2   1.0
9 (38) 414 327e   ND ND
10 (40) 474 396e   ND ND
19 (M; 51) 1A 1 (0) 350 !5e 7.7 5.4  4.7
2 (5) 369 23e 7.8 5.6  5.1
3 (8) 255f 58,000e 7.4 5.1  4.8
4 (13) 250 336e 7.7 5.2 + 4.8
5 (14) 259 27e 7.8 5.4  4.9
6 (20) 323 !6e 7.3 5.0  4.2
7 (24) 365 20e 7.7 5.2  4.7
8 (27) 360 !5e 7.6 5.2 + 4.7
9 (33) 465 !15e 7.1 5.1  4.4
20 (M; 43) 1B 1 (0) 715 26e 7.6 2.3  2.2
2 (3) 715 !5e 7.1 2.0  1.8
3 (7) 640 33 6.9 2.3  2.1
4 (10) 613 6 6.7 2.7  2.4
5 (14) 752 !4 7.0 2.9  2.6
6 (19) 716 7323 6.5 2.4  2.0
7 (23) 626 5149 6.8 2.0  1.5
8 (28) 564 7774 6.7 2.6  2.0
9 (31) 408 3084 6.5 2.6  1.6
10 (33) 410 16e 6.6 3.1  2.5
21 (F; 41) 4 1 (0) 749 !5e 6.4 4.8  4.4
2 (5) 873 10 6.1 4.9  4.3
3 (8) 900f 2509 6.0 4.3  3.8
4 (13) 949 17,466 5.7 4.1  3.6
5 (19) 633 9466 6.4 4.3  3.3
6 (24) 494 3123 6.2 3.6  3.1
7 (26) 427 11,195 6.8 3.4 + 3.4
8 (29) 392 7310 6.4 4.1  4.0
9 (34) 513 8370 6.4 4.3  3.8
10 (39) 357 6190 6.9 4.4  3.7
NOTE. Except for patient 13, who experienced primary infection and spontaneous clearance, all patients showed chronic seropositivity for HCV.
Patients 16 and 18 underwent treatment with peginterferon/ribavirin at the end of the observational period. PBMC, peripheral-blood mononuclear cell.
a NA, not available.
b Nos. indicate months after the collection of the earliest sample; underlined nos. denote the sample/time points randomly chosen for cross-sectional
analysis.
c Mean of 2 independent samples.
d A plus sign (+) denotes that the sample tested positive for HCV RNA but was below the level of reliable quantification; a minus sign () denotes
that the sample was negative for HCV RNA; “ND” denotes that analysis was not performed, because sample was limited.
e Patient was undergoing antiretroviral therapy.Interpolated from adjacent time points (2 months after RNA determination).
f Patient was undergoing antiretroviral therapy.
1716 • JID 2006:194 (15 December) • Kaiser et al.
Figure 1. Quantitation of positive- and negative-strand hepatitis C virus (HCV) RNA. A, Results of conventional 1-step reverse transcription (RT)
polymerase chain reaction (PCR) procedure. The presence of high concentrations of multiple oligonucleotides during RT favors synthesis of by-products
of unspecific amplification. Premature substrate consumption may entail loss of specific amplification signals at late cycles. B, Separation of cDNA
synthesis and PCR. Sequestration of PCR primers by means of a paraffin layer releasing reactants only during “hot-start” activation of the thermostable
Taq polymerase results in improvement of both sensitivity and accuracy of quantitation. C, Strand-specific quantitative RT-PCR assay for negative-
strand HCV RNA. Reactions with an input of up to 2.5  105 copies of positive-strand HCV RNA remained negative, representing a differentiation
of 103–104 between HCV positive- and negative-strand RNA.
been reported to be associated with the presence of HCV in
maternal PBMCs [21].
Despite considerable evidence for extrahepatic replication,
PBMC-associated HCV RNA does not necessarily reflect solely
viral replication. Because of HCV’s propensity to bind to a wide
range of cells possibly nonpermissive for HCV replication [22,
23], an as-yet-uncharacterized proportion of viral RNA may
represent virions nonspecifically attached to blood cells. Hence,
viral dynamics in PBMCs remain largely unexplored, despite
considerable evidence for extrahepatic replication. To address
these issues, we quantified HCV RNA, of positive and negative
polarity, with respect to its long-term course and relation to
PBMCs, using novel techniques allowing for selective assess-
ment of viral RNA enclosed within cell-attached virions.
PATIENTS, MATERIALS, AND METHODS
Patients and specimens. A total of 87 samples of plasma and
87 corresponding samples of PBMCs were obtained from 30
HIV/HCV-coinfected persons monitored at the University Hos-
pital Zu¨rich center who were enrolled in either the Early An-
tiretroviral Treatment Study [24], the Swiss Spanish Intermit-
tent Treatment Trial [25–27], or the Simplified Maintenance
Therapy Trial [28]. Selection of patients for the present study
was based on positive serological results for HCV. The trials
had been approved by the Ethics Review Committee, and all
subjects had provided written informed consent to provide
frozen blood samples for further virological examinations. Basic
demographic and virological characteristics of the patients are
listed in table 1. PBMCs were isolated from anticoagulated
blood by Ficoll-gradient purification and were stored at80C.
Differential extraction of HCV RNA. RNA from 0.14 mL
of plasma was extracted by use of a QIAamp Viral RNA kit
(QIAGEN). Total RNA from “dry” pellets of PBMCs was ex-
tracted, in the presence of synthetic internal-standard RNA
coding for murine prion protein (mPrP), by use of the RNeasy
mini kit (QIAGEN) [29].
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Figure 2. Evaluation of freeze-thaw nuclease (FTN)–digestion protocol
for use with hepatitis C virus (HCV). Viremic plasma was spiked, on
pellets, in dilution series of 5 106 HCV-negative peripheral-blood mono-
nuclear cells and was extracted either directly or after FTN digestion.
HCV RNA copies were quantified by reverse-transcription polymerase
chain reaction. The amounts of HCV RNA were highly correlated: the
slope of the linear regression line was not significantly different from 1
( ), and the y intercept was not significantly different from 0Pp .124
( ).Pp .96
HCV RNA in virions attached to PBMCs was extracted from
“dry” pellets by freeze-thaw nuclease (FTN) digestion [29, 30].
In brief, pellets were thawed and resuspended in 130 mL of PBS
containing 10 mmol/L Tris HCl, 1 mmol/L MgCl2, 1 mg/mL
DNAse I (Roche), and 1.8 mg/mL RNAse A (QIAGEN). Sam-
ples were snap-frozen on dry ice, were thawed twice, and then
were incubated, with constant agitation, at 37C for 60 min.
To inactivate nucleases, protease (10 mL, 50 mg/mL; QIAGEN
Protease) was added, and incubation was continued for 45 min.
The lysates were mixed with Buffer RLT (QIAGEN) supple-
mented with 1% b-mercaptoethanol, 10 mg/mL carrier RNA,
and internal-standard mPrP RNA [29]. Extraction efficiency
was controlled by quantitation of internal-standard RNA, and
samples with low (!10%) extraction efficiency were excluded
from analysis. Samples of RNA from healthy donor PBMCs
were extracted in parallel and were used as negative controls
(6 per PCR plate).
One-tube, 2-phase reverse-transcription polymerase chain
reaction (RT-PCR) assays. Positive-strand HCV RNA was
quantified by duplicate real-time RT-PCR using sense primer
ME81 [31] (5′-CTGCGGAACCGGTGAGTACACC-3′), reverse/
cDNA primer Ky78 [32] (5′-CTCGCAAGCACCCTATCAGG-
CAGT-3′), and dual-labeled fluorescent probe mf190 (5′-FAM-
TAGCCGAGTAGTGTTGGGTCGCGAA-3′-TAMRA).
RT-PCR was performed in 96-well PCR plates by a single-
tube system (QIAGEN 1-step RT-PCR kit) modified with an
additional “hot start” using 15 mL of paraffin wax (Fluka) to
separate reverse transcription from the amplification steps (fig-
ure 1A and 1B), under conditions described elsewhere [33, 34].
For specific detection of HCV negative-strand RNA (figure
1), 10 mL of template RNA was reverse transcribed as follows:
RNA was incubated, at 65C for 5 min, in a volume of 21 mL
in the presence of 0.2 mmol/L biotinylated primer mf209 (BIO-
5′-AAAGCGTCTAGCCATGGCGTTAGTA-3′) and 0.5 mmol/
L dNTP. Subsequently, 7 mL of 4 reaction buffer containing
56 U of ribonuclease inhibitor RNaseOUT (Invitrogen), 200 U
of SuperScript III reverse transcriptase (Invitrogen), and 0.14
mmol of dithiothreitol was added, and the mixture was incu-
bated at 50C for 45 min and at 70C for 15 min. Recovery of
specific cDNA was performed by use of streptavidin magnetic
particles (Roche) (figure 1C): 2.2 mg of equilibrated streptavidin
magnetic beads was incubated with cDNA, under constant ag-
itation at 25C for 60 min, in 0.1 mL of TEN100 (10 mmol/
L Tris-HCl, 1 mmol/L EDTA, 100 mmol/L NaCl, pH 7.5, 0.1%
Triton X-100). Beads were washed 3 times each with TEN1000
(with 1 mol/L NaCl) and TN50 (50 mmol/L NaCl). Beads were
resuspended in 30 mL of Hotmaster PCR mix. For additional
specificity, PCR was preceded by linear multiplication of specific
cDNA, by use of Hotmaster Taq polymerase (Vaudaux-Eppen-
dorf) and 0.2 mmol/L primer mf202 (5′-ACGAGACCTCCCGG-
GGCACTCGCAA-3′), in a 30-mL volume, at 95C for 2 min;
PCR comprising 15 cycles of denaturation at 95C for 10 s,
annealing at 60C for 10 s, and extension at 72C for 60 s was
performed. A 2-mL portion of preamplified cDNA was sub-
sequently PCR-quantified in real time during 40 cycles of de-
naturation at 95C for 10 s, annealing and extension at 60C
for 60 s, by use of 30 mL of HotStar Taq master mix supple-
mented with 1.5 mmol/L MgCl2, 1 mmol/L ME81, 1 mmol/L
Ky78, and 0.3 mmol/L mf190tq. Calibration was performed by
use of i-cycler software (Bio-Rad).
Quantitation of mPrP mRNA and glyceraldehyde-3-phos-
phate dehydrogenase mRNA was performed as reported else-
where [33].
Synthetic standard RNA of either positive- or negative-strand
polarity was produced by T7 polymerase–mediated in vitro
transcription of PCR products [35]: The 5′ untranslated region
of patient 20 (nt 1–395, numbered according to the H77 se-
quence in the HCV-sequence database of the National Institute
of Allergies and Infectious Diseases (http://hcv.lanl.gov/content/
hcv-db/index) was amplified by RT-PCR using T7 promotor-
tailed amplification primers, and RNA was transcribed by use
of an Ampliscribe T7 flash-transcription kit (Epicentre). RNA
was treated with DNAse I repeatedly and was purified by use
of RNeasy columns, and concentrations were measured by pho-
tometry at 260 nm. External standards were prepared by serial
Figure 3. Course of plasma and peripheral-blood mononuclear cell (PBMC)–associated hepatitis C virus (HCV) RNA over time. A, Longitudinal course
of HCV RNA load in plasma () and of total () and virion-enclosed () PBMC-associated HCV RNA in patients 16–21. Correlation coefficients and
P values derived from linear regression analyses of the correlation between total PBMC-associated and plasma HCV RNA are indicated within the
graphs. Time points at which RNA levels were below the limit of detection (as indicated in the graphs for patients 16 and 18) were excluded from
analyses. Patients 16 and 18 achieved sustained viral response by the end of the observational period; downward-pointing arrows (f) indicate initiation
of treatment. Note the pronounced fluctuations in viremia in plasma from patients 17 and 18, as well as the parallel kinetics of cellular HCV RNA.
Plasma HCV RNA load was normalized per 1 mL, and PBMC-associated HCV RNA load was normalized per 5  106 cells. NS, not significant. B,
Ratios between total PBMC-associated HCV RNA and HCV RNA loads in plasma, in patients 13–21. Plasma HCV RNA load was normalized per 1
mL, and PBMC-associated HCV RNA load was normalized per 5  106 cells.
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Figure 4. Distribution of peripheral-blood mononuclear cell (PBMC)–associated hepatitis C virus (HCV) RNA. Data points both for samples included
in the initial cross-sectional analysis () and from longitudinal analyses () are shown. A, Correlation between virion-enclosed and intracellular HCV
RNA. The level of intracellular HCV RNA was calculated by subtraction of virion-enclosed from total cell-associated HCV RNA. B, Virion-enclosed HCV
RNA as a percentage of total cellular HCV RNA. The horizontal bar indicates the geometric mean (40%).
dilution of synthetic RNA, and assay sensitivities were assessed
by limiting-dilution analysis.
Statistics. HCV RNA measurements were normalized ac-
cording to 1 mL of plasma or an input cell count of 5  106,
and statistical analyses were performed on log10-transformed
values. Intracellular HCV RNA was calculated as the difference
between total and virion-enclosed PBMC-associated HCV RNA.
Parametric procedures (paired t test, linear regression) were
used for the logarithmic data set; otherwise, either the Mann-
Whitney test, Spearman’s signed-rank test, or the Kruskal-Wal-
lis test was used. Data points at which measurements of intra-
cellular or extracellular PBMC-associated HCV RNA loads fell
below the limits of detection were excluded from correlation
analyses.
Correlation within the combined data set was assessed by
robust linear regression accounting for multiple and unbal-
anced sampling. Statistic analyses were performed by use of
GraphPad Prism4.0 software (AMPL Software) and Stata (ver-
sion 9.2; StataCorp).
RESULTS
Differential extraction and quantitation of HCV RNA. HCV
RNA was quantified by a novel real-time RT-PCR assay with
enhanced sensitivity and accuracy (figure 1); this assay mini-
mizes amplification of by-products by using a layer of paraffin
wax to prevent cDNA synthesis of amplification primers. Spe-
cific and reproducible amplification (figure 1B) was detected
over a linear range from 6 log10 units down to a detection
limit of !5 copies per reaction.
To detect negative-strand HCV RNA, we developed an assay
that used biotinylated primers to ensure specificity by affinity
purification of properly primed cDNA; this assay (figure 1C)
revealed precise reproducibility of quantitation within a linear
range from3 log10 down to a detection limit of 50–100 copies
per reaction. An input of 2.5  105 copies of complementary
positive-strand RNA gave rise to an occasional positive signal,
because of either truly false priming events or amplification of
residual template DNA within the RNA standard; however,
because the inputs from samples from patients invariably were
!5  104 HCV positive-strand RNA copies per PCR, the spec-
ificity of the assay can be assumed to be quite sufficient to
ensure the validity of the results.
To assess the distribution of HCV RNA within different com-
partments of peripheral blood, we quantified positive-strand
HCV RNA in (1) plasma; (2) direct, “total” PBMC extracts
(total PBMC-associated HCV RNA); and (3) extracts derived
exclusively from virions attached to PBMCs (virion-enclosed
PBMC-associated HCV RNA). The intracellular fraction of
PBMC-associated HCV RNA was calculated as the difference
between items (2) and (3) from replicate samples; negative-
strand HCV RNA, not being incorporated within viral particles,
was quantified only in (2).
Selective isolation of virion-enclosed PBMC-associated HCV
RNA included disintegration of cells by repeated FTN digestion
[29, 30] and relied on the virions’ resistance to such treatment.
To validate the procedure, we performed model experiments
using HCV particles from high-HCV-titer- plasma from the pa-
tients. We found that HCV RNA copy numbers in FTN-digested
samples correlated highly with the amounts recovered by direct
RNA extraction ( ; ) (figure 2), without a2r p 0.976 P ! .0001
significant difference in yield ( , by paired t test), therebyPp .96
confirming that the HCV particles were completely resistant to
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Table 2. Correlation between plasma and peripheral-blood
mononuclear cell (PBMC)–associated levels of hepatitis C virus
(HCV) RNA.
Sample
PBMC-associated HCV RNA
Total Virion enclosed Intracellular
Cross-section of patients 1–21
r2 0.167 0.191 0.089
P .066 .047 .246
Combined data setsa
r2 0.263 0.358 0.220
P .044 .018 .068
a Robust linear regression accounting for multiple sampling was used.
FTN digestion; conversely, intracellular nucleic acids, as quan-
tified by use of glyceraldehyde-3-phosphate dehydrogenase
RNA, were reduced to 2.1% (95% confidence interval [CI],
0.7%–3.6%) of those in directly extracted samples.
PBMC-associated HCV RNA: partial intracellular location.
In a cross-sectional analysis of plasma samples from 30 HIV/
HCV-seropositive patients (6 women and 24 men; median age,
38 years), 21 specimens tested positive for HCV RNA, with
viral loads of 3.9–8.3 log10 copies (median, 6.8 log10 copies)
(table 1). No HCV RNA was detected in any of the PBMC
extracts from the 9 patients with plasma in which no HCV was
detectable; conversely, all PBMC samples from patients with
HCV-positive plasma tested positive for HCV RNA, which was
1.7–5.6 log10 copies (normalized to an input of 5  10
6 cells)
in directly extracted samples and 1.3–5.6 log10 copies in FTN-
digested samples (table 1). Thus, we observed widespread pres-
ence of viral RNA in PBMCs from HCV-viremic patients but
did not find evidence for persistence of HCV in PBMCs in the
absence of HCV viremia in plasma. Moreover, the amounts of
virion-enclosed HCV RNA were consistently lower than those
of total PBMC-associated HCV RNA ( , by paired tPp .0025
test); thus, a significant proportion of cell-associated HCV RNA
was found to reside intracellularly, indicating HCV infection
of PBMCs.
As a marker of ongoing replicative activity of HCV in
PBMCs, we determined the occurrence of negative-strand HCV
RNA in total PBMC RNA extracts (table 1). HCV negative-
strand replicative intermediates could be detected in 9.6% of
all PBMC samples that tested positive for positive-strand HCV
RNA, accounting for sporadic detection in 28.5% of all patients
with HCV viremia. Exact quantitation of positive samples was
generally precluded by the low copy numbers (!50 RNA copies
per reaction) of negative-strand RNA samples, which indicates
that the prevalence of negative-strand RNA might have been
underestimated because of limitations in sensitivity.
Furthermore, in terms of both CD4 cell count (median, 494
[range, 131–1336] vs. 508 [26–842] cells/mL; ] and HIVPp .93
load in plasma (median, 50 [range, !3–3.9  106] vs. 25 [!5–
54,200]/mL; ), the HCV RNA–positive patients did notPp .53
differ from the HCV RNA–negative patients (table 1). Although
some patients started or stopped highly active antiretroviral
treatment during the observation period, no significant asso-
ciation with any of the above-mentioned markers was observed
( ).P .34
Course of PBMC-associated HCV RNA over time. Sequen-
tial measurements of plasma, total, and virion-enclosed PBMC-
associated HCV RNA were performed in a subset of patients
(table 1). Patients 16–21 underwent repeat sampling (4–10
times) over time periods of 17–40 months, which allowed de-
tailed longitudinal analyses (figure 3A). Except for patients 16
and 18 (who, by the end of the observation period, experienced
treatment-induced clearance of viremia in plasma), HCV RNA
loads in plasma showed no overall increase or decrease over
time ( ). Patients 17 and 18 had patterns of pronouncedPp .56
fluctuations: 110-fold changes in plasma levels of HCV within
1 year. The course of total as well as virion-enclosed PBMC-
associated HCV RNA levels revealed similar characteristics: no
overall increase or decrease over time ( and ,Pp .27 Pp .28
respectively) and, albeit less pronounced than those for viremia
in plasma, fluctuations of 0.5–1.5 log10. Again, intracellular
HCV RNA was consistently present.
Correlation between virion-enclosed and intracellular HCV
RNA in PBMCs. Virion-enclosed and intracellular HCV RNA
were strongly correlated ( ; ) in cross-sec-2r p 0.801 P ! .0001
tional analysis (figure 4A), a result that reflects that a consistent
proportion—approximately half (geometric mean, 51% [95%
CI, 39%–68%])—of total PBMC-associated HCV RNA was
enclosed within virions. Longitudinal data confirmed this bal-
anced distribution (geometric mean, 40% [95% CI, 35%–46%)
(figure 4). To determine whether an apparently bimodal dis-
tribution of this proportion among patients could be assigned
to host or viral factors, interdependencies with virological
(plasma or cellular HCV RNA loads, HCV genotype, HIV load,
and antiretroviral treatment), immunological (lymphocyte,
monocyte, and CD4 cell counts), or potentially confounding
(cell pellet size, clinical trial, and age of sample) factors were
assessed by correlation analyses and rank tests of association
( in all cases). Moreover, the proportion of virion-en-P 1 .16
closed HCV RNA did not significantly differ between patients
( , by Kruskal-Wallis test).P 1 .3
Limited correlation between plasma and PBMC-associated
HCV RNA. HCV RNA was observed solely in the PBMCs
from patients with detectable HCV viremia; notably, HCV RNA
became undetectable in the PBMCs of patients who experienced
spontaneous (in the case of patient 13) or treatment-induced
(in the case of patients 16 and 18) resolution of HCV viremia
(table 1). Thus, it is conceivable that, in PBMCs, a significant
contribution to the measured HCV RNA loads might come
from free virus binding on leukocyte surfaces. However, the
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association between viral loads in plasma and PBMC-associated
HCV RNA was weak in cross-sectional analysis and, at most,
of only borderline significance (table 2). To further elucidate
this possibly weak interdependency, which might have been
obscured by patient- and virus-specific factors, intrapatient cor-
relation analysis of sequential samples was performed. In 2 of
6 patients, a significant association between plasma and total
PBMC HCV RNA could be detected (figure 3A). Again, inter-
dependency may have been concealed by the typically narrow
range of virological fluctuation and by the limitations of the
data set. Conversely, in patients with more-pronounced changes
in plasma HCV RNA loads (patients 17 and 18), the course of
PBMC-associated HCV RNA appeared to mirror the course of
viremia; adjusted analysis of the combined data set revealed
comparably weak but significant interdependence (table 2).
Thus, the level of viremia in plasma might partly, but not
entirely, account for the observed variation in PBMC-associated
HCV RNA. Furthermore, the ratio of total cell-associated HCV
RNA to plasma HCV RNA differed between patients but was
relatively stable, over time, for a given patient ( ) (figureP ! .001
3B). This finding suggests the importance of additional, host-
or virus-specific determinants that affect systemic HCV repli-
cation, both in plasma and in PBMCs.
DISCUSSION
The mounting evidence for extrahepatic replication of HCV in
vivo [5–12] relies mainly on findings of a qualitative nature,
whereas little is known about viral dynamics in the PBMC
compartment. Moreover, the relative contributions of HCV
RNA within either the cells or virions attached to the cells have
not been examined so far.
The presence of approximately equal amounts of intracellular
and virion-enclosed HCV RNA associated with PBMCs, as
clearly demonstrated in our analysis during chronic infection
but also in a single primary case (patient 13), confirms the
evidence for HCV infection of PBMCs in vivo. However, it
remains unresolved whether there was active ongoing repli-
cation in the analyzed PBMC specimens; the fact that intra-
cellular HCV RNA was strongly correlated with virion-enclosed
HCV RNA, whereas levels of viremia in plasma were only
loosely associated with cellular viral load, may be interpreted
as being supportive of virus production in PBMCs, by the
argument that the cell-associated virions attached to PBMCs
may originate directly from intracellular production, rather
than reflect viral particles captured from the plasma surround-
ing these cells.
Conversely, replicative intermediates were detected in only
a minority (9.5%) of the samples tested. This result may be
due to the limitations of the sensitivity of the assay of HIV
negative-strand RNA, or it may indicate low replicative activity
in PBMCs. Hence, intracellular HCV RNA might represent viral
particles that have fused solely with the cell membrane and are
not going to replicate themselves there. Such virions, which are
engaged in the early entry process, are expected to be sensitive
to FTN digestion and would qualify as “intracellular” in our
analysis. In preliminary experiments, we have observed that
nuclease sensitivity of otherwise completely FTN digestion–
resistant plasma-derived HCV RNA may be induced in vitro
by binding of HCV to primary human leukocytes but not to
some immortalized human T and hepatoma cell lines (M.F.
and P.K., unpublished data). These in vitro observations, which
are reminiscent of ongoing viral entry, suggest that intracellular
PBMC-associated HCV RNA in vivo might to some extent
reflect ongoing fusion of virions in plasma. Thus, at least some
of the infected cells may not actively transcribe the viral genome
at a given time point but, rather, may passively carry intracel-
lular viral-RNA genomes.
Although the present study found that plasma and cell-as-
sociated HCV RNA are subject to some common constraints,
the relatively low strength of their correlations suggests, in
accordance with the results of previous reports [36–38], dif-
ferential regulation of PBMC-associated HCV RNA, by as-yet-
unknown host- or virus-specific factors. In contrast, propor-
tions of cell-associated HCV RNA load versus plasma HCV
RNA load were observed to be patient specific and relatively
stable over time. Thus, the ratio of plasma and cellular HCV
burden may be characteristic of host-virus interaction and
might mirror the infectivity that the predominant viral quasi
species in plasma has for the patient’s PBMCs.
To our knowledge, the present study is the first in which
PBMC-associated HCV RNA has been both quantified with
regard to its intra- versus extracellular localization and com-
pared longitudinally to viral loads in plasma over a time period
of up to several years (figure 3A). HCV RNA concentrations
in plasma were found to have relatively stable courses without
progressive changes. These findings are in concordance with
reports that monitor viral loads in plasma over comparable
periods [39–41], although other studies have indicated increases
in HCV viremia [42, 43]. These discrepancies may be explained
by the longer periods of observation and the differences in the
patient populations (e.g., HIV coinfection) and assays used.
The course of PBMC-associated HCV RNA, both in the total
and in the virion-enclosed fraction, was found to be equally
steady over time and appeared to mirror the course of virus
concentrations in plasma. Notably, typical major fluctuation
[44, 45] of the virus in the plasma of patients 17 and 18 cor-
responded to changes in the cellular compartment (figure 3A).
Furthermore, successful antiviral treatment of patients 16 and
18 reduced PBMC-associated HCV RNA to undetectable levels
before completely clearing it from plasma, a finding that is con-
sistent with the lack of detection of HCV RNA in the PBMCs
of patients whom the cross-sectional analysis had shown to
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have undetectable viral loads in plasma (table 1). This latter
finding contradicts reports of prolonged HCV persistence in
the PBMC compartment when viremia is absent [19, 46]. More
precisely, Radkowski et al. [19] have detected HCV RNA of
both polarities in the leukocytes of patients experiencing years
of sustained viral response. Occasionally, HCV was also de-
tectable in serum and liver samples, suggesting the presence of
more-widespread low-level persistence. Conversely, Castillo et
al. [46] have reported HCV RNA in the PBMCs of patients
with “occult” HCV infection, which implies undetectable serum
HCV RNA loads but does not exclude its presence in the liver.
Given the almost single-copy sensitivity of our PCR assay for
positive-strand HCV RNA, methodological flaws are unlikely
to have obviated detection of persistent HCV RNA, whereas
the restricted sample size in our study represents a potential
limitation that should be considered. On all accounts, our find-
ings reveal that HCV-infected long-lived leukocytes are, at most,
extremely rare in the peripheral blood.
In conclusion, our experiments reveal a substantial contri-
bution of intracellular to total PBMC-associated HCV RNA.
Although our findings describe a setting of HIV/HCV coin-
fection and remain to be confirmed for monoinfection, they
support a concept of low-level replication in PBMCs. Indis-
putably, our data suggest that infection and expression of HCV
in PBMCs is of minor quantitative importance for systemic
replication and persistence of HCV; nevertheless, HCV infec-
tion of PBMCs may influence pathogenesis, not only as an
independent reservoir but also because infected PBMCs might
carry and deliver virions into other potential HCV reservoirs.
Particularly in view of the notable patient specificity of HCV
RNA loads in PBMCs, future studies should investigate whether
this readily accessible cellular compartment of HCV infection
provides any independent predictive value for either the early
prognosis of the course of disease or its response to treatment.
Acknowledgments
We thank our patients, for their commitment to the study; R. Hafner,
D. Baumann, C. Grube, and C. Schneider, for excellent patient care; C.
Vo¨gtli and I. Nievergelt, for administrative assistance; F. Burgener, for
laboratory assistance; B. Ledergerber, for statistical advice; A. Zinkernagel,
for helpful discussions; and J. Wong, for support and critical review of the
manuscript.
References
1. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for
hepatitis C virus extrahepatic replication sites in patients with acquired
immunodeficiency syndrome: specific detection of negative-strand viral
RNA in various tissues. Hepatology 1998; 28:1398–401.
2. Carrozzo M, Quadri R, Latorre P, et al. Molecular evidence that the
hepatitis C virus replicates in the oral mucosa. J Hepatol 2002; 37:364–9.
3. Arrieta JJ, Rodriguez-Inigo E, Ortiz-Movilla N, et al. In situ detection of
hepatitis C virus RNA in salivary glands. Am J Pathol 2001; 158:259–64.
4. Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C
virus negative-strand RNA sequences and analysis of viral sequences
in the central nervous system: evidence of replication. J Virol 2002;
76:600–8.
5. Wang JT, Sheu JC, Lin JT, Wang TH, Chen DS. Detection of replicative
form of hepatitis C virus RNA in peripheral blood mononuclear cells.
J Infect Dis 1992; 166:1167–9.
6. Takyar ST, Li D, Wang Y, Trowbridge R, Gowans EJ. Specific detection
of minus-strand hepatitis C virus RNA by reverse-transcription poly-
merase chain reaction on PolyA(+)-purified RNA. Hepatology 2000;
32:382–7.
7. Castillo I, Pardo M, Bartolome J, et al. Occult hepatitis C virus infection
in patients in whom the etiology of persistently abnormal results of
liver-function tests is unknown. J Infect Dis 2004; 189:7–14.
8. Sansonno D, Iacobelli AR, Cornacchiulo V, Iodice G, Dammacco F.
Detection of hepatitis C virus (HCV) proteins by immunofluorescence
and HCV RNA genomic sequences by non-isotopic in situ hybrid-
ization in bone marrow and peripheral blood mononuclear cells of
chronically HCV-infected patients. Clin Exp Immunol 1996; 103:414–21.
9. Roque-Afonso AM, Ducoulombier D, Di Liberto G, et al. Compart-
mentalization of hepatitis C virus genotypes between plasma and pe-
ripheral blood mononuclear cells. J Virol 2005; 79:6349–57.
10. Laskus T, Radkowski M, Wang LF, Nowicki M, Rakela J. Uneven dis-
tribution of hepatitis C virus quasispecies in tissues from subjects with
end-stage liver disease: confounding effect of viral adsorption and
mounting evidence for the presence of low-level extrahepatic repli-
cation. J Virol 2000; 74:1014–7.
11. Ducoulombier D, Roque-Afonso AM, Di Liberto G, et al. Frequent
compartmentalization of hepatitis C virus variants in circulating B cells
and monocytes. Hepatology 2004; 39:817–25.
12. Bare P, Massud I, Parodi C, et al. Continuous release of hepatitis C
virus (HCV) by peripheral blood mononuclear cells and B-lympho-
blastoid cell-line cultures derived from HCV-infected patients. J Gen
Virol 2005; 86:1717–27.
13. Revie D, Braich RS, Bayles D, et al. Transmission of human hepatitis
C virus from patients in secondary cells for long term culture. Virol
J 2005; 2:37.
14. Zuckerman E, Zuckerman T. Hepatitis C and B-cell lymphoma: the
hemato-hepatologist linkage. Blood Rev 2002; 16:119–25.
15. Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr. Reemergence of
hepatitis C virus after 8.5 years in a patient with hypogammaglobu-
linemia: evidence for an occult viral reservoir. J Infect Dis 2005; 192:
1088–92.
16. Everson GT. Should we treat patients with chronic hepatitis C on the
waiting list? J Hepatol 2005; 42:456–62.
17. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of
patients with decompensated cirrhosis to prevent recurrence of hep-
atitis C after liver transplantation. J Hepatol 2003; 39:389–96.
18. Feld JJ, Liang TJ. HCV persistence: cure is still a four letter word.
Hepatology 2005; 41:23–5.
19. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of
hepatitis C virus in patients successfully treated for chronic hepatitis
C. Hepatology 2005; 41:106–14.
20. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov
NV, Michalak TI. Hepatitis C virus persistence after spontaneous or
treatment-induced resolution of hepatitis C. J Virol 2004; 78:5867–74.
21. Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A.
Vertical transmission of HCV is related to maternal peripheral blood
mononuclear cell infection. Blood 2000; 96:2045–8.
22. Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding
to platelets and 2 mononuclear cell lines. Blood 2001; 98:2293–300.
23. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved
in signal transduction and cell adhesion in the immune system. Annu
Rev Immunol 1998; 16:89–109.
24. Opravil M, Cone RW, Fischer M, et al. Effects of early antiretroviral
treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized
Distribution of HCV RNA in PBMCs • JID 2006:194 (15 December) • 1723
trial of double versus triple therapy. Swiss HIV Cohort Study. J Acquir
Immune Defic Syndr 2000; 23:17–25.
25. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of struc-
tured treatment interruptions in human immunodeficiency virus in-
fection. Arch Intern Med 2003; 163:1220–6.
26. Fischer M, Hafner R, Schneider C, et al. HIV RNA in plasma rebounds
within days during structured treatment interruptions. Aids 2003; 17:
195–9.
27. Joos B, Trkola A, Fischer M, et al. Low human immunodeficiency virus
envelope diversity correlates with low in vitro replication capacity and
predicts spontaneous control of plasma viremia after treatment inter-
ruptions. J Virol 2005; 79:9026–37.
28. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of sim-
plified maintenance therapy with abacavir, lamivudine, and zidovudine
in human immunodeficiency virus infection. J Infect Dis 2002; 185:
1251–60.
29. Fischer M, Wong JK, Russenberger D, et al. Residual cell-associated
unspliced HIV-1 RNA in peripheral blood of patients on potent an-
tiretroviral therapy represents intracellular transcripts. Antivir Ther
2002; 7:91–103.
30. Fischer M, Joos B, Wong JK, et al. Attenuated and nonproductive viral
transcription in the lymphatic tissue of HIV-1-infected patients re-
ceiving potent antiretroviral therapy. J Infect Dis 2004; 189:273–85.
31. Margraf RL, Page S, Erali M, Wittwer CT. Single-tube method for
nucleic acid extraction, amplification, purification, and sequencing.
Clin Chem 2004; 50:1755–61.
32. Young KK, Resnick RM, Myers TW. Detection of hepatitis C virus
RNA by a combined reverse transcription-polymerase chain reaction
assay. J Clin Microbiol 1993; 31:882–6.
33. Roscic-Mrkic B, Fischer M, Leemann C, et al. RANTES (CCL5) uses
the proteoglycan CD44 as an auxiliary receptor to mediate cellular
activation signals and HIV-1 enhancement. Blood 2003; 102:1169–77.
34. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Gunthard HF.
Cellular viral rebound after cessation of potent antiretroviral therapy
predicted by levels of multiply spliced HIV-1 RNA encoding nef. J
Infect Dis 2004; 190:1979–88.
35. Cone RW, Schlaepfer E. Improved in situ hybridization to HIV with
RNA probes derived from PCR products. J Histochem Cytochem 1997;
45:721–7.
36. Blackard JT, Smeaton L, Hiasa Y, et al. Detection of hepatitis C virus
(HCV) in serum and peripheral-blood mononuclear cells from HCV-
monoinfected and HIV/HCV-coinfected persons. J Infect Dis 2005;
192:258–65.
37. Furione M, Maserati R, Gatti M, et al. Dissociation of serum and liver
hepatitis C virus RNA levels in patients coinfected with human im-
munodeficiency virus and treated with antiretroviral drugs. J Clin Mi-
crobiol 2004; 42:3012–6.
38. Rodriguez-Inigo E, Casqueiro M, Navas S, Bartolome J, Pardo M,
Carreno V. Fluorescent “in situ” hybridization of hepatitis C virus RNA
in peripheral blood mononuclear cells from patients with chronic hep-
atitis C. J Med Virol 2000; 60:269–74.
39. Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC.
Sequential serum hepatitis C viral RNA levels longitudinally assessed
by branched DNA signal amplification. Hepatology 1998; 28:1702–6.
40. Hollingsworth RC, Sillekens P, van Deursen P, Neal KR, Irving WL.
Serum HCV RNA levels assessed by quantitative NASBA: stability of
viral load over time, and lack of correlation with liver disease. The
Trent HCV Study Group. J Hepatol 1996; 25:301–6.
41. Yoshimura E, Hayashi J, Ueno K, et al. No significant changes in levels
of hepatitis C virus (HCV) RNA by competitive polymerase chain
reaction in blood samples from patients with chronic HCV infection.
Dig Dis Sci 1997; 42:772–7.
42. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis
C virus RNA levels in hemophiliacs: relationship to human immu-
nodeficiency virus infection and liver disease. Multicenter Hemophilia
Cohort Study. Blood 1994; 84:1020–3.
43. Sabin CA, Emery V, Devereux HL, et al. Long-term patterns of hepatitis
C virus RNA concentrations in a cohort of HIV seronegative men with
bleeding disorders. J Med Virol 2002; 68:68–75.
44. Arase Y, Ikeda K, Chayama K, et al. Fluctuation patterns of HCV-RNA
serum level in patients with chronic hepatitis C. J Gastroenterol 2000;
35:221–5.
45. Halfon P, Bourliere M, Halimi G, et al. Assessment of spontaneous
fluctuations of viral load in untreated patients with chronic hepatitis
C by two standardized quantitation methods: branched DNA and Am-
plicor Monitor. J Clin Microbiol 1998; 36:2073–5.
46. Castillo I, Rodriguez-Inigo E, Bartolome J, et al. Hepatitis C virus
replicates in peripheral blood mononuclear cells of patients with occult
hepatitis C virus infection. Gut 2005; 54:682–5.
